Exploring Physicians’ Knowledge, Attitudes, and Practices Regarding SGLT2 Inhibitors among diabetic patients in the North West Bank of Palestine

Background Sodium–glucose cotransporter 2 (SGLT2) inhibitors improve outcomes in type 2 diabetes mellitus (T2DM) and are now recommended for cardio-renal protection in appropriate patients. Evidence from Palestine on physicians’ preparedness to prescribe SGLT2 inhibitors is limited. Methods We conducted a descriptive cross-sectional online survey (October 2025–February 2026) among physicians involved in diabetes care across hospitals and primary healthcare centers in the Northwest Bank of Palestine. The questionnaire assessed knowledge (4 items), attitudes (4 items), and perceived barriers to prescribing SGLT2 inhibitors. Composite knowledge (0–4) and attitude (0–8) scores were calculated and categorized as low, moderate, or high. Associations between physician characteristics and scores were examined using independent-samples t-tests and one-way ANOVA with Tukey post-hoc comparisons. Results In total, 121 physicians participated. Knowledge was limited (mean 1.36 ± 0.83), and 57.9% were classified as having low knowledge. Attitudes were generally positive (mean 4.82 ± 2.20; n = 119 complete cases), with 38.7% classified as having high attitudes. Years of clinical experience were associated with higher knowledge (p = 0.040) and more favorable attitudes (p < 0.001). Attitude scores also differed by specialty (p = 0.008) and professional status (p < 0.001). Cost and limited knowledge were the most frequently reported barriers. Conclusions Physicians in the Northwest Bank reported willingness to use SGLT2 inhibitors, but important practical knowledge gaps remain. Targeted education—especially for early-career and primary care physicians—alongside measures to improve affordability and access may support guideline-concordant prescribing.